How long should I take Mobocertinib?

Mobocertinib (Mobocertinib) is a targeted drug used to treat non-small cell lung cancer (NSCLC), especially for EGFR (epidermal growth factor receptor) mutations, particularly those with theT790M mutation, a resistance mutation that renders conventional EGFR inhibitors ineffective. Mobosetinib is an oral medication, and the duration of taking it is usually determined based on the patient's specific condition and doctor's advice.

The course of treatment with mobosetinib is usually long-term, and its goal is to continuously inhibitEGFR mutations and control tumor growth. During treatment, doctors will regularly monitor the patient's condition and adjust the medication plan based on the tumor's response and the patient's tolerance. Typically, patients will need to continue taking moboxetinib until one of the following conditions occurs:

1.The effect is no longer obvious: If the tumor stops responding to the drug, or drug resistance develops, the doctor may consider changing the treatment plan.

2.Adverse reactions: If the patient experiences serious adverse reactions or drug tolerance issues, the doctor may suspend treatment or reduce the dose.

3.The patient's condition changes: If a patient's lung cancer status changes, the treatment plan may need to be re-evaluated.

Mobotinib is currently on the market in China, but it is not included in medical insurance. Patients need to pay for it in full, so the price is very high. Please consult the local hospital pharmacy for specific prices. Other versions include the Hong Kong version of the original drug Mobotinib, which costs around 7,000 to 8,000 yuan. The generic drug of Mobotinib is mainly a Laotian generic drug. The price is about three to four thousand yuan, which is nearly half cheaper than the original drug. The ingredients of the original drug and the generic drug are the same.